Cardiol Therapeutics Inc. has announced a significant move in its financial strategy by filing a prospectus supplement to offer up to $75 million in Class A common shares. This decision, made on November 3, 2026, is intended to enhance the company’s financial position and support its ongoing growth initiatives.

The offering is being conducted under the terms of the corporation's registration statement on Form F-10. The shares will be sold through Jefferies LLC, which will act as the agent for the distribution. The sales are classified as "at-the-market distributions," meaning they will occur at prevailing market prices without a minimum amount required to be raised.

Cardiol Therapeutics, incorporated in Ontario, Canada, operates in the biological products industry, specifically focusing on therapeutic products. The company trades on the Nasdaq under the ticker CRDL. This latest move follows a series of recent filings, including two 6-K forms on the same day, showcasing the company's active engagement with its investors and regulatory bodies.

According to the filing, the company has entered into a sales agreement with Jefferies LLC, allowing it to distribute the offered shares in the United States. The shares will not be sold on the Toronto Stock Exchange or other Canadian markets. The agent will receive a 3% commission on the gross proceeds from the sale of the shares.

The prospectus supplement indicates that the proceeds from this offering will be used for various corporate purposes, although specific details were not disclosed in the filing. The company aims to leverage these funds to enhance its operational capabilities and potentially accelerate its research and development efforts.

Investors should be aware that this offering carries a degree of risk, as indicated in the prospectus. The shares are considered speculative, and potential investors are advised to consult with financial advisors before making any decisions.

As for the broader implications, this move by Cardiol Therapeutics reflects a trend in the biological products industry, where companies are increasingly seeking to raise capital through share offerings. This could lead to heightened competition as firms vie for investor attention and funding.

Looking ahead, Cardiol Therapeutics has not specified what the next steps will be following this filing. However, the company is expected to continue its efforts to meet the listing requirements for the offered shares on both the Nasdaq and the Toronto Stock Exchange.

For more information, the complete prospectus supplement can be accessed through the SEC's EDGAR database, under accession number 0001104659-26-122171.